Alvotech (ALVO)

The company develops and manufactures biosimilar candidates for disease areas including autoimmune conditions, eye disorders, osteoporosis and cancer. Its portfolio is identified through AVT product codes, including programmes such as AVT02, AVT03, AVT04, AVT05 and AVT06. These medicines target large biologic markets where physicians, payers and health systems may seek lower-cost alternatives to established branded therapies.

Alvotech’s strategy combines in-house development and manufacturing capabilities with commercial partnerships in different regions. This model allows the company to concentrate on the scientific, regulatory and production complexity of biosimilars while using partners to support market access, distribution and local commercial execution. Its revenue base is geographically diversified, with Europe representing the largest contributor, followed by the United States and other international markets.

What sets Alvotech apart is its exclusive commitment to biosimilars and its emphasis on biologic manufacturing expertise. Producing biosimilars requires demonstrating analytical, clinical and quality comparability to reference products, which creates higher technical barriers than many traditional generic medicines. For investors, the company is linked to regulatory approvals, launch timing, partner execution, manufacturing reliability and the expanding global effort to reduce biologic drug costs.